ENTITY
FDA places partial clinical hold on Merck and Daiichi Sankyo’s I-DXd lung cancer trial after interstitial lung disease deaths
FDA partial clinical hold; ifinatamab deruxtecan; I-DXd; IDeate-Lung02; Merck; Daiichi Sankyo; small cell lung cancer; interstitial lung disease; grade 5 ILD; antibody-drug conjugate; clinical trial deaths
White House unveils nine new “most-favored-nation” drug pricing deals
most-favored-nation pricing; MFN; drug pricing; White House; Trump administration; pharmaceutical manufacturers; Ozempic; Wegovy; Eli Lilly; Novo Nordisk; prescription drug costs; US healthcare policy
Recent Biotech News: Altimmune’s Pemvidutide Advances in MASH, Emerging China Obesity Players, and Ipsen Phase 2 Setback
Altimmune; pemvidutide; MASH; Phase 2b; IMPACT trial; FDA; China obesity; Ipsen; Phase 2 fail
Insmed Delivers Rare Disappointment as Brinsupri Flops in Mid-Stage Rhinosinusitis Study
Insmed; Brensocatib; Brinsupri; DPP1 inhibitor; chronic rhinosinusitis without nasal polyps; mid-stage trial; Phase 2b; nasal inflammation; trial failure; biotech stocks; INS1148 acquisition
Endpoints News Topics at 2026 JPM Healthcare Conference: CEOs, Investors, China, and Beyond
JPM Healthcare Conference; Endpoints News; CEOs; investors; AI healthcare; biopharma; private equity
Moderna Lands CEPI as New Backer for Its Pandemic Flu (H5 Bird Flu) Program
Moderna; CEPI; Coalition for Epidemic Preparedness Innovations; pandemic influenza; H5 bird flu; mRNA vaccine; Phase 3 trial; pandemic preparedness; vaccine development; funding
Quantori and Expert Systems Partner to Accelerate Drug Discovery with Foundational Predictive AI Models
Quantori; Expert Systems; drug discovery; AI models; Q-Scientist; pharmaceutical R&D
Coloplast announces changes to Executive Leadership Team
Coloplast; Executive Leadership Team; ELT changes; Interventional Urology; People & Culture; Kevin Hardage; Tommy Johns; leadership transition; management changes
Ipsen’s Fidrisertib Fails Primary Endpoint in Pivotal Phase II FALKON Trial for Rare Bone Disease FOP
Ipsen; fidrisertib; FALKON trial; FOP; Phase II failure; heterotopic ossification
GSK strikes RNA-based neuro and kidney disease collaboration with CAMP4 Therapeutics
GSK; CAMP4 Therapeutics; RNA therapeutics; regulatory RNA; antisense oligonucleotides; ASO; RAP Platform; neurodegenerative diseases; kidney disease; renal disease; gene upregulation; biotech collaboration; licensing deal; milestone payments; tiered royalties